Reuters logo
BRIEF-Genmab and GSK gets EU approval for Arzerra in combination
July 3, 2014 / 1:26 PM / 3 years ago

BRIEF-Genmab and GSK gets EU approval for Arzerra in combination

COPENHAGEN, July 3 (Reuters) - Danish biotech company Genmab :

* GlaxoSmithKline (GSK) and Genmab receive EU authorization for Arzerra (Ofatumumab) as first-line treatment for chronic lymphocytic leukemia (Cll) in combination with chlorambucil or bendamustine for patients ineligible for flud

* Approval based on phase III data from study with ofatumumab + chlorambucil & phase II data from study with ofatumumab and bendamustine

Source text for Eikon: Further company coverage: (Reporting by Copenhagen newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below